Business Wire

Clearstream Signs on to Regnology’s Rcloud Platform for Regulatory Reporting

2.8.2023 09:00:00 EEST | Business Wire | Press release

Share

Regnology, a leading software provider with a focus on regulatory reporting solutions, announced today that its client Clearstream Banking AG, central securities depository and leading provider of global post-trade services, has signed on to use its Rcloud technology (powered by Google Cloud Platform (GCP)). While the migration is still subject to regulators’ approvals, Clearstream’s intent to move from on-premise regulatory reporting to the cloud highlights the reliability and security of the Rcloud platform. Regnology launched its Rcloud solution in partnership with Google Cloud in November 2022.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801538424/en/

Clearstream, Deutsche Börse Group’s post-trade business for the global markets, offers one of the most comprehensive international securities services available, settling more than 250,000 transactions daily for customers in over 110 countries. Being an international financial infrastructure provider, Clearstream abides by strict compliance requirements of German and Luxembourg authorities.

“Clearstream’s decision to move to the Rcloud platform is a landmark moment because of the trust that Clearstream put in our technological partnership with Google Cloud,” said Antoine Moreau, Chief Technology Officer at Regnology.

“As one of our valued clients, Clearstream Banking AG has relied on our regulatory expertise and technology to support their reporting obligations for years. Due to its position and status as one of Europe’s most heavily regulated entities, Clearstream’s selection of Rcloud speaks volumes about their trust in our depth of knowledge and the added scalability and performance benefits of our cloud solution. We see cloud adoption acceleration amongst our customers and believe our regulatory expertise team with the GCP know-how can help build the foundation for an industry cloud approach to financial services regulatory reporting,” added Maciej Piechocki, Regnology’s Chief Revenue Officer.

“With our hybrid, multi-cloud strategy, Deutsche Börse Group sets new standards for cloud innovation across the financial services industry. We are very satisfied to be one of the first institutions to sign on to the Rcloud platform. In Regnology, we found an excellent partner for the next step on Clearstream’s cloud journey, supporting our clients with state-of-the-art regulatory reporting solutions,” said Clearstream Banking AG CTO, Volker Riebesell.

The Rcloud platform delivers ultra-elastic scalability along with reliable and fast report submission and always up-to-date reporting data and software, offering all the benefits of a modern regulatory-as-a-service solution. Going beyond standard cloud frameworks, Rcloud offers improved deployment and infrastructure-as-code services, run and change management automation, and additional benefits including self-service via the Regnology Cloud portal, and future-proofed architecture for additional services and products. Regnology’s partnership with Google Cloud, which matches 100% of its electricity consumption with renewable energy purchases, also ensures that sustainability is built into the platform.

About Regnology

Regnology is a leading technology firm on a mission to bring safety and stability to the financial markets. With an exclusive focus on regulatory reporting and more than 35,000 financial institutions, 70 regulators, international organizations and tax authorities relying on our solutions to process their regulatory reporting data, we’re uniquely positioned to bring greater data quality, efficiency, and cost savings to all market participants. With over 900 employees in 17 countries and a unified data ingestion model powering our work, our clients can quickly implement and derive value from our solutions and easily keep pace with ongoing regulatory changes. Regnology was formed in 2021 when BearingPoint RegTech, a former business unit of BearingPoint Group, joined forces with Vizor Software, a global leader in regulatory and supervisory technology. The company is on a continued organic and external growth path, building up as one of the most recognized regulatory reporting powerhouses in the world.

For more information about Regnology, connect with us on LinkedIn and Twitter.

Visit our website: www.regnology.net

About Clearstream

Clearstream is the innovative and trusted post-trade business for the global markets. It runs the leading securities and funds servicing ecosystems of tomorrow.

The company operates the German and Luxembourg central securities depositories and an international central securities depository for the Eurobonds market. With 17 trillion Euros in assets under custody, it is one of the world’s largest settlement and custody firms for domestic and international securities.

It also delivers premier fund execution, distribution, data and reporting services, covering over 50 fund markets worldwide.

Clearstream is part of Deutsche Börse Group, an international exchange organisation and provider of innovative market infrastructures.

To learn more, visit us at www.clearstream.com or connect via LinkedIn.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mireille Adebiyi, Chief Marketing Officer, Regnology
info@regnology.net

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release

Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven

Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release

Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti

PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release

Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr

Celltrion to Spotlight Subcutaneous (SC) Infliximab (Remsima™ SC) and Broader IBD Portfolio at UEG Week 202615.10.2026 03:10:00 EEST | Press release

Celltrion, Inc. (KRX:068270) announced its participation in United European Gastroenterology (UEG) Week 2026, in Barcelona, Spain (Oct. 17-20), highlighting its inflammatory bowel disease (IBD) treatment portfolio, led by Remsima™ SC (subcutaneous infliximab). Celltrion will showcase its comprehensive infliximab portfolio, comprising Remsima™ intravenous (IV) and subcutaneous (SC) formulations, as well as the Remsima™ IV liquid formulation launched in Europe earlier this year.1 Additionally, the company will highlight its broader IBD portfolio, including SteQeyma™ (ustekinumab) and Yuflyma™ (adalimumab), reflecting its continued efforts to expand treatment options for patients with IBD.2,3 On October 18, Celltrion will host a symposium titled "Navigating the Treatment Journey with Subcutaneous Infliximab Across Clinical Scenarios," Chaired by Professor Peter M. Irving of King's College London, UK, a leading IBD expert. Celltrion will also host two MTE sessions at its booth. In the firs

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye